Clinical Trial: A Multicenter, Randomized, Open-Label, Phase II Trial Comparing Neoadjuvant Tislelizumab Plus Chemotherapy Versus Tislelizumab Plus Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma (China)

China, Nov. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Randomized, Open-Label, Phase II Trial Comparing Neoadjuvant Tislelizumab Plus Chemotherapy Versus Tislelizumab Plus Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135678

Registration Time: 2026/11/01

Type: Interventional study

Primary Sponsor: Fujian Medical University Union Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344424

Published by HT Digital Content Services with permission from Health Daily Digest....